RxDoctor Payments Data

Deidre Langston

Nurse Practitioner · Vandalia, ILNPI 1710307681

Payments from drug & device makers

$1,326in general payments, 2019–2025

Across 67 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$291
  • AstraZeneca$241
  • Preventric Diagnostics, Inc.$179
  • Lilly USA, LLC$114
  • Novartis$111
  • Neurocrine Biosciences, Inc.$64
  • plus $327 from 11 others

What the payments were for

  • Food & beverage$1,326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,326 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$53,873
Medicare patients
213
Services billed
781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$51,399
XareltoRivaroxaban30$17,407
JanuviaSitagliptin Phosphate15$14,741
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,117
LinzessLinaclotide14$11,970
TrulicityDulaglutide11$11,732
Tresiba Flextouch U-100Insulin Degludec20$11,625
BelsomraSuvorexant18$7,523
Potassium Chloride114$2,989
Gabapentin74$2,889
Albuterol Sulfate HfaAlbuterol Sulfate47$1,662
Montelukast Sodium175$1,649
SynthroidLevothyroxine Sodium39$1,483
Donepezil Hcl27$1,322
Levothyroxine Sodium193$1,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$51,39961 claims
AbbVieLinzess, Synthroid$16$13,45353 claims
GSKTrelegy Ellipta$15$12,11719 claims
Lilly USA, LLCTrulicity$114$11,73211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Vandalia

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →